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DObjective: Patients with coronary artery disease complicated by moderate ischemic mitral regurgitation have
demonstrably poorer outcome than do patients with coronary artery disease but without mitral regurgitation.
The optimal treatment of this condition has become increasingly controversial, and a randomized trial evaluating
current practices is warranted.
Methods:We describe the design and initial execution of the Cardiothoracic Surgical Trials Network Surgical
Interventions for Moderate Ischemic Mitral Regurgitation Trial.
Results: This is an ongoing prospective, multicenter, randomized, controlled clinical trial designed to test the
safety and efficacy of mitral repair in addition to coronary artery bypass grafting in the treatment of moderate
ischemic mitral regurgitation.
Conclusions: The results of the Cardiothoracic Surgical Trials Network Surgical Interventions for Moderate
Ischemic Mitral Regurgitation Trial will provide long-awaited information on controversial therapies for this
morbid disease process. (J Thorac Cardiovasc Surg 2012;143:111-7)Supplemental material is available online.
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The Journal of Thoracic and Cavalve apparatus. It results from postinfarction left ventricu-
lar dysfunction and dilatation (remodeling), papillary
muscle displacement with leaflet tethering, and progressive
annular dilatation.1,2 It is often associated with a regional
wall motion abnormality and coronary artery disease in
the corresponding territory. Structural or organic mitral
regurgitation, on the other hand, connotes a distinct
pathology of the mitral valve, most commonly
myxomatous degeneration, mitral valve prolapse, or
Barlow disease. Each of these pathologic entities may
lead to chronic nonischemic mitral regurgitation.
The presence of IMR is a significant predictor of adverse
short- and long-termoutcomes in patientswith coronaryartery
disease, particularly after acute myocardial infarction.3-6
When coronary artery disease is treated with coronary artery
bypass grafting (CABG) alone, the unadjusted incidence of
death has been found to be significantly increased even in
the presence of only mild IMR (8.4% at 1 year) relative to
patients with no IMR (3.8% at 1 year). The mortality risk
increases with increasing severity of mitral regurgitation
and has been found to be twice as great in patients with
moderate IMR treated with CABG alone (16.9% at
1 year).7 The surgical treatment of IMR has become increas-
ingly controversial, with approximately equal numbers of
patients treated with either combined CABG and mitral
valve repair or replacement or with CABG alone.8-10
Operative mortality for CABG as well as for CABG
combined with mitral valve repair has declined steadily
nationwide during the past 5 years11; however, the additionalrdiovascular Surgery c Volume 143, Number 1 111
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CTSN ¼ Cardiothoracic Surgical Trials
Network
ERO ¼ effective regurgitant orifice
IMR ¼ ischemic mitral regurgitation
LVESVI ¼ left ventricular end-systolic volume
index
NHLBI ¼ National Heart, Lung, and Blood
Institute
TEE ¼ transesophageal echocardiography
TTE ¼ transthoracic echocardiography
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Daortic crossclamp time and cardiopulmonary bypass time as-
sociatedwith the performance ofmitral valve repair increase
the risk of the combined procedure.12,13 This approach does
not allow a purely off-pump procedure. Selection of the
appropriate patients is thus imperative to ensure that the
trade-off of the additional risk of mitral valve repair is nec-
essary and provides additional short- or long-term benefit.
Proponents of treatingmild tomoderate IMRwith revascu-
larization alone argue that revascularization improves re-
gional contractility and restores mitral valve papillary
muscle continuity, thus normalizingmitral valve function.14,15
On the other hand, proponents of a more aggressive treatment
strategy cite the negative consequences of ongoing mitral
regurgitation. Myocardial revascularization alone may be
insufficient to restore normal ventricular physiology once
mitral regurgitation has developed. Correction of mitral
regurgitation may prevent progressive adverse remodeling,
improve cardiac function, and attenuate the risk of heart
failure.
Available evidence addressing treatment decisions for
IMR is limited to small, single-center, randomized trials,
observational studies, and case series,7-11,13,15 in which
correction for significant and substantial imbalances in
baseline patient characteristics is problematic, making it
difficult to develop a clear understanding of appropriate
treatment options. These studies are also limited by
variable definitions of the severity and etiology of mitral
regurgitation, variable surgical repair techniques, potential
publication bias, limited patient follow-up, and lack of in-
formation on key secondary outcomes such as quality of
life.12 Importantly, the recently published American Col-
lege of Cardiology and American Heart Association guide-
lines both for CABG and for the management of patients
with valvular heart disease avoid addressing the decision al-
gorithm for IMR.16,17 The only consensus established from
literature review is that the preferred treatment is unknown
and should be individualized and that a randomized clinical112 The Journal of Thoracic and Cardiovascular Surgtrial to generate necessary evidence on which to base
clinical decisions is essential.7,11,18,19TRIAL DETAILS
In February 2004, the National Heart, Lung, and Blood
Institute (NHLBI) advisory council proposed that the
NHLBI evaluate the status of cardiac surgery and its future
directions. The NHLBI convened a working group on future
directions in cardiac surgery, which called for the formation
of the Cardiothoracic Surgical Trials Network (CTSN),
which was designed to develop a culture of rigorous clinical
evaluative research within the field of cardiac surgery. The
CTSN includes integration of both cardiologists and sur-
geons in the ownership of and responsibility for trials bridg-
ing the integrated specialties. Moderate IMR was the top
priority for initial investigation of both the NHLBI working
group and the CTSN investigators.18Trial Objectives
The CTSN Surgical Interventions for Moderate Ischemic
Mitral Regurgitation Trial seeks to evaluate the safety and
efficacy of mitral valve repair for moderate IMR. Specifi-
cally, the trial compares mitral valve repair combined with
CABG to CABG alone in this patient population. The pri-
mary aim of the trial is to evaluate the effects of these 2 sur-
gical approaches on left ventricular remodeling, as assessed
by left ventricular end-systolic volume index (LVESVI).
Secondary aims of this trial include assessment of the effects
of these 2 surgical interventions on the severity of the mitral
regurgitation, regional and global cardiac performance,
mortality, adverse events, quality of life, functional status,
neurocognitive function, and health resource use.Trial Design
This is a prospective, multicenter, randomized clinical
trial conducted at the clinical centers participating in the
CTSN (Appendix E1). Patients deemed eligible are ran-
domly assigned in a 1:1 allocation to CABG combined
with mitral valve repair or CABG alone (Figure 1). The
enrollment period is estimated to be 36 months, and all
patients will be followed up for 24 months after randomiza-
tion. A minimum of 2 years of follow-up is intended, al-
though the primary end point will be assessed at 1 year.
Neither patients nor investigators are blinded to the
treatment assignment because of the nature of treatment
intervention. The investigators are, however, blinded to all
data from other clinical sites, with the exception of informa-
tion required for institutional review board reporting pur-
poses. All protocol-defined echocardiograms are analyzed
by a centralized core laboratory, and all core laboratory per-
sonnel are blinded to clinical characteristics and outcomes.
Serious and protocol-defined adverse events are adjudicated
by an independent event adjudication committee. Trialery c January 2012
FIGURE 1. Study design flow chart. MR, Mitral regurgitation; CABG,
coronary artery bypass grafting; LVESVI, left ventricular systolic volume
index; LOS, length of stay; LVEF, left ventricular ejection fraction; AE’s,
adverse events.
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monitoring board appointed by the NHLBI.
Patient Population
The patient population for this trial consists of patients
with clinically significant coronary artery disease and an in-
dication for CABG associated with moderate IMR. The is-
chemic etiology and degree of mitral regurgitation is
assessed by transthoracic echocardiography (TTE) within
30 days before randomization, as determined by the clinical
site echocardiographer. All clinical site laboratories are ac-
credited by the echocardiography core lab with regard to
both image acquisition and interpretation before site activa-
tion and patient enrollment. Patients are eligible to partici-
pate regardless of the presence or absence of symptoms
attributable to mitral regurgitation. Furthermore, to increase
the generalizability of the results of this trial, because the
timing of referral for surgical intervention in patients with
moderate IMR is quite variable in the community, the trial
was designed in the absence of a ‘‘run-in’’ period that wouldThe Journal of Thoracic and Caotherwise have optimized medical therapy before the qual-
ifying TTE. As such, patients can be included in the trial
even if subsequent TTEs after the qualifying TTE, but be-
fore randomization, demonstrate a decrease in the severity
of mitral regurgitation with optimal medical therapy. Pa-
tients who have echocardiographic documentation of severe
IMR by TTE at any time are candidates for a separate CTSN
trial comparing mitral valve repair and replacement.
Echocardiographic Assessment of the Degree of
Mitral Regurgitation
This trial is designed to evaluate a patient population
within the clinical spectrum of moderate IMR, as identified
by TTE. The initial mitral valve inclusion criteria were an
effective regurgitant orifice (ERO) 0.2 cm2 to 0.39 cm2 in
area7,11,18 and a structurally normal mitral valve. It became
clear early in the course of screening patients for
enrollment, however, that the ERO area criterion was overly
restrictive and led to the exclusion of patients with other
semiquantitative echocardiographic measures of moderate
mitral regurgitation. Review of trial screening logs indicated
that failure to meet the original ERO area criterion, despite
the consensus opinion of the surgical principal investigator
and the site echocardiographer that the mitral regurgitation
was moderate, was the major cause of screening failure.
The echocardiographic inclusion criteria were therefore
broadened to reflect more closely the consensus of surgeons
and cardiologists in an effort to ensure that enrolled patients
more closely resembled those referred in clinical practice.
Specifically, inclusion was redefined as moderate IMR
with (1) an ERO area of 0.2 cm2 to 0.39 cm2 or (2) an ERO
area less than 0.2 cm2 and additional evidence of more than
mild mitral regurgitation, as suggested by such integrative
criteria as the density of the mitral regurgitation velocity
profile, pulmonary vein systolic flow abnormalities, and
left atrial jet area (Tables 1 and 2).7,11,18,20
Eligibility Criteria
Criteria for inclusion in this trial, beyond the echocardio-
graphic identification of moderate IMR, are intentionally
broad, focusing on targeting patients with coronary anat-
omy amenable to CABG and a clinical indication for revas-
cularization. Patients are excluded from participation if they
have evidence of concomitant structural mitral valve dis-
ease, previous mitral valve intervention, or planned con-
comitant intraoperative procedures, with the exception of
maze procedures or closure of a patent foramen ovale or
an atrial septal defect. The key eligibility criteria for the
trial are listed in Table 3.
Randomization
Randomization is blocked and stratified by clinical cen-
ter. Randomization is performed intraoperatively, after the
sternotomy but before cannulation of the aorta, to minimizerdiovascular Surgery c Volume 143, Number 1 113
TABLE 1. Integrative method criteria for echocardiographic assessment of degree of mitral regurgitation: Echocardiographic color Doppler and
quantitative criteria
Mild Moderate Severe
Color flow jet area <20% of LA area 20%–39% of LA area Large central jet (usually>10 cm2
or>40% of LA area) or variable
size wall-impinging jet swirling in LA
Quantitative parameters
Vena contracta width (cm) <0.30 0.30–0.69 0.70
Effective regurgitant orifice area (cm2) <0.20 0.20–0.39 0.40
LA, Left atrium.
Acquired Cardiovascular Disease Smith et al
A
C
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pected surgical contraindications to mitral valve repair.
The timing of randomization was chosen to ensure both
that cannulation for cardiopulmonary bypass is possible
and that patients with structural mitral valve pathology
identified by intraoperative transesophageal echocardiogra-
phy (TEE) not detected on the original TTE study are ex-
cluded before randomization. The randomization process
is controlled centrally and performed through a web-
based data-collection system that automates the delivery
of randomization codes. The treatment assignment is sent
to the site coordinator electronically in a secure fashion,
and electronic verification of the treatment assignment is re-
quired before proceeding with the treatment intervention.
Thereafter, primary efficacy is to be analyzed by intention
to treat; that is, the patients are grouped by their assignment
at randomization regardless of whether they actually re-
ceive the treatment to which they are initially assigned.End Point Definitions
The primary end point for the trial is the degree of left
ventricular remodeling, as assessed by the LVESVI mea-
sured by TTE at 12 months after randomization. The prin-
cipal secondary end point is a composite of major adverse
cardiac events, as defined by an unweighted composite
score composed of the following components: death, stroke,
worsening heart failure (1 New York Heart Association
class), hospitalization for heart failure, and mitral valve
reintervention. Additional secondary end points include
all-cause mortality, functional status assessed by peak vol-
ume of oxygen uptake during cardiopulmonary exerciseTABLE 2. Integrative method criteria for echocardiographic assessmen
criteria
Structural Doppler parameters Mild
Left atrial size Normal Norm
Left ventricular size Normal Norm
Mitral leaflets or support apparatus Normal or abnormal Norm
Mitral inflow (pulsed wave) A wave dominant Varia
Jet density (continuous wave) Incomplete or faint Dens
Jet contour (continuous wave) Parabolic Usua
Pulmonary vein flow Systolic dominance Systo
114 The Journal of Thoracic and Cardiovascular Surgtesting, quality of life (36-item Short Form Health Survey,
Duke Activity Status Index, and Minnesota Living with
Heart Failure questionnaire), and health care costs.Treatment Intervention
Procedural technique. All patients enrolled in this trial
undergo CABG according to each operating surgeon’s tech-
nical preference, with the exception of cardiopulmonary by-
pass support, which is required for all patients in the trial.
For those patients randomly assigned to undergo mitral
valve repair in addition to CABG, the repair is performed
with standard techniques but the protocol mandates the
use of a complete ring and downsizing by 2 sizes whenever
possible. The other elements of operative and perioperative
clinical care are not prescribed by the protocol.
Surgeon certification. To minimize the effect of variation
in operator expertise for the purposes of this clinical trial, all
surgeons operating on patients enrolled in the trial must
meet a minimum threshold of experience and be certified
by the site principal investigator. Protocol-specified surgical
certification requires that the surgical investigator perform
a minimum of 10 mitral valve repair procedures per year,
averaged over 2 years. A certified clinical site surgeon
must participate in the mitral valve procedure of a patient
enrolled at that site if the primary surgeon is not certified.Follow-up
Postrandomization data collection occurs at predeter-
mined study visits as well as at event-driven visits. Planned
study visits include the first postoperative day and postop-
erative months 6, 12, and 24. Blood, urine, and tissuet of degree of mitral regurgitation: Echocardiographic supportive
Moderate Severe
al or dilated Usually dilated
al or dilated Usually dilated
al or abnormal Abnormal, flail leaflet, ruptured papillary muscle
ble E wave dominant (usually 1.2 m/s)
e Dense
lly parabolic Early-peaking triangular
lic blunting Systolic flow reversal
ery c January 2012
TABLE 3. Selected eligibility criteria
Inclusion criteria
1. Moderate mitral regurgitation in the judgment of the clinical site
echocardiographer, as assessed by transthoracic echocardiography
with the integrative method
2. Coronary artery disease amenable to coronary artery bypass grafting
and a clinical indication for revascularization
3. Age 18 y
4. Ability to sign informed consent and release of medical information
forms
Key exclusion criteria
1. Any evidence of structural (chordal or leaflet) mitral valve disease
2. Inability to derive effective regurgitant orifice and left ventricular
end-systolic volume index by transthoracic echocardiography
3. Planned concomitant intraoperative procedures (with exception of
maze procedure or closure of patient foramen ovale or atrial septal
defect)
4. Previous surgical or percutaneous mitral valve intervention
5. Contraindication to cardiopulmonary bypass
6. Clinical signs of cardiogenic shock at the time of randomization
7. Treatment with long-term intravenous inotropic therapy at the time of
randomization
8. ST-segment elevation myocardial infarction requiring intervention
within 7 days before randomization
Smith et al Acquired Cardiovascular Disease
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Dsample collections are performed intraoperatively, and
additional blood and urine collections are made 6 and 12
months after randomization. Physical examination, New
York Heart Association functional classification, angina
class determination, echocardiography, and quality of life
assessment are performed at postoperative months 6, 12,
and 24. Cardiopulmonary exercise testing is performed (if
possible) at baseline and at 6 and 12 months. Neurocogni-
tive testing is performed at baseline and 12 postoperative
months. Direct cost data are obtained quarterly for all
randomized patients. A minimum of 2 years of follow-up
is intended, although the primary end point is determined
at 1 year.
Sample Size
For calculation of sample size, we assumed the mean
baseline LVESVI in the target population to be 80 mL/m2
(normal LVESVI approximately 25 mL/m2). For patients
randomized to undergo CABG only, we anticipate a 5%
reduction in LVESVI, or an absolute change of 4 mL/m2.
A clinically important additional reduction of 12 mL/m2,
or a total reduction of 20% (16 mL/m2) is estimated for
patients who undergo mitral valve repair in addition to
CABG. Assuming that baseline and 12 month LVESVI in
both arms follow a gamma distribution with a common
SD of 35 mL/m2, a total of 300 patients, randomized with
equal probability to each arm provides approximately
90% power to detect this additional difference of 12 mL/m2
in LVESVI.The Journal of Thoracic and CaPrimary Analysis
The primary null hypothesis will be tested in an intent-to-
treat analysis with a .05 level 2-tailed Wilcoxon rank sum
test. The choice of the Wilcoxon rank sum test for the pri-
mary analysis was motivated by the expectation of a rela-
tively substantial amount of nonignorable missing data,
primarily as a result of patient death; 1-year mortality is ex-
pected to range from 10% to 15% and may differ between
randomization arms.Additional Analyses
The details of the bypass operation performed (number of
grafts placed, quality of grafts, and target vessels) and as-
sessment of regional and global left ventricular function
at 6, 12, and 24 months will allow examination of the suc-
cess of the revascularization component of the procedure.
The interaction between the preoperative plan for revascu-
larization, any variation from the plan, the resulting change
in global and regional left ventricular function, and associ-
ated change in the severity of IMR will thus be evaluated.
This analysis may identify patient subpopulations that differ
in meeting the primary and secondary end points and are
perhaps more responsive to revascularization alone.DISCUSSION
The cardiac surgical community has not been recognized
historically for the conduct of large-scale, multicenter, com-
parative effectiveness or translational clinical trials. The de-
cision to investigate the surgical treatment options for IMR
has provided the opportunity to identify investigational is-
sues that will be relevant to all future surgical clinical
research.
It is clear that one element for success is the creation of
a culture of surgical investigation that is dissociated from
the treatment paradigms that have been developed in the ab-
sence of evidence from randomized clinical trials. The sec-
ond element of success is a shared vision of cardiac surgical
investigation with the cardiology community at each site,
within each region, and nationally. The effort must begin
with engaged and committed surgical leadership at each
clinical site, coupled with diplomatic and persistent engage-
ment of the cardiology community. The nature of a patient
referral for surgery generally confers the expectation on the
part of each participant that a specific procedure will be per-
formed. Although expectations must be adjudicated at the
local level, patients, surgical investigators, and their refer-
ring physicians must eventually be willing to embrace par-
ticipation in a randomized trial to provide greater insight
into best practices. No single formula works to achieve
this goal; however, lessons have been learned through the
CTSN that will help future trials.
One important lesson concerns enrollment. The core
CTSN clinical sites were activated for enrollment as ofrdiovascular Surgery c Volume 143, Number 1 115
Acquired Cardiovascular Disease Smith et al
A
C
DApril 2009. Initially, the accrual rate was substantially less
than estimated by historical rates of combined CABG and
mitral valve procedures at the clinical sites. An extensive
evaluation of the protocol, the structure of the CTSN, and
site performance characteristics was undertaken, including
multidisciplinary visits to each site. This evaluation
disclosed several obstacles and inefficiencies that were
amenable to improvement by protocol modification and es-
tablishment of the clear expectation that each site develop
a culture of clinical research to include surgeons and cardi-
ologists in collaboration.
It became clear that the historical prevalence of IMR had
been significantly overestimated through historical reliance
on contrast ventriculography and qualitative TTE and TEE
estimates of the degree of mitral regurgitation. A review of
the Duke Cardiovascular Database revealed that patients of-
ten have a change in mitral regurgitation severity grade
when evaluated by TEE in the operating room. In a series
of 430 patients with both preoperative TTE and intraopera-
tive TEE, 19% of patients with mild mitral regurgitation
documented preoperatively were found to have moderate
mitral regurgitation in the operating room. Among patients
who had moderate mitral regurgitation preoperatively, 14%
were found to have severe mitral regurgitation in the oper-
ating room. The clinical decision making in these cases was
undoubtedly driven by the intraoperative TEE findings;
however, such patients would not be eligible for this trial.
The more common occurrence of a reduction in the severity
of mitral regurgitation seen on intraoperative TEE (37% of
cases of preoperative moderate mitral regurgitation deter-
mined intraoperatively to be mild) does not prevent enroll-
ment in the protocol as designed, because the qualifying
echocardiogram is the preoperative TTE study. The proto-
col development committee, in collaboration with the
echocardiographic core laboratory leadership, therefore
recommended that the determination of degree of mitral re-
gurgitation be made by the site echocardiographer from the
TTE according to all the primary and secondary criteria
outlined in Tables 1 and 2.
Site visits with surgeons, cardiologists, and institutional
leadership, as well as reviews of screening logs and meet-
ings of the CTSN steering committee, provided new in-
sights into the interactions among patients, referring
cardiologists, site cardiologists, and surgeons that influence
trial conduct and enrollment. It became clear that the car-
diovascular community has developed paradigms for the
management of patients with IMR that are not evidence
based but could affect patient recruitment.
Treatment of patients with coronary artery disease and
IMR has generally related to a qualitative assessment of
the severity of mitral regurgitation, the presence of heart
failure symptoms, and the correlation of coronary artery
disease with myocardial ischemia, viability, and function.
In the setting of moderate IMR, treatment paradigms are116 The Journal of Thoracic and Cardiovascular Surgeasily biased and may in some instances lead to a premature
recommendation for mitral valve surgery that can preclude
randomization into the trial once the expectation for repair
has been established in the patient’s mind. The generaliz-
ability of the study results may also be negatively affected
if only patients with IMR toward the lower end of the mod-
erate scale are enrolled. Similar concerns have been raised
regarding patient recruitment in trials of percutaneous pat-
ent foramen ovale closure. CTSN cardiologists and sur-
geons realized that joint evidence-based decision making
and clinical equipoise would be required to enable patient
enrollment.
The dynamic nature of IMR was also found to be a major
impediment to patient enrollment. Clinically indicated TTE
studies, performed with variable image acquisition, were
frequently found to demonstrate suitable IMR severity but
failed to capture either the primary end point measure
(LVESVI) or the ERO area. Subsequent research TTE
studies, performed under the conditions of optimal medical
therapy for ischemia and after diuresis, frequently then
failed to meet the criteria for mitral regurgitation severity.
Thus although such patients had the appropriate substrate
for enrollment in the trial and underwent treatment for
IMR of the severity seen on presentation, they were not
eligible for randomization. This finding led to site-specific
improvements in the quality of clinical TTE, thus enabling
capture of the key elements of IMR in patients at initial
presentation.
A systematic review of screening failures also revealed
several limiting exclusion criteria, including previous car-
diac surgery, planned concomitant surgical correction of
atrial fibrillation, and a rigid threshold defining exclusion
for pulmonary hypertension regardless of its relationship
to the degree of mitral regurgitation. Revisions to the eligi-
bility criteria were approved by the data and safety monitor-
ing board in May 2009.
After this intensive 2-month period of self-evaluation and
modifications to the protocol, a new target accrual rate (12.4
patients per month) was established. The current enrollment
rate meets expectations. In addition, criteria were estab-
lished within the CTSN for the incorporation of ancillary
and satellite sites, and 12 additional sites have been acti-
vated. As of this writing, the Surgical Interventions for
Moderate Ischemic Mitral Regurgitation Trial has enrolled
144 patients, or 48% percent of the target study population.
The process of creating and implementing an effective in-
vestigational network to address significant cardiac surgical
problems has been enlightening. The design of this trial, and
our experience in conducting it, has revealed limitations in
the application of observational data to patient care. The
absence of robust randomized trial evidence regarding the
treatment of IMR has severely limited the ability of sur-
geons and cardiologists to determine the best options for
these patients.ery c January 2012
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